Minerva Neurosciences, Inc.
Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016
WALTHAM, Mass., 2016-06-01 14:30 CEST (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2016 Healthcare Conference on June 8, 2016 at 11:00 a.m. Eastern Time.
The Company will present further data from the Phase IIb trial with MIN-101 in schizophrenia and the Phase IIa trial with MIN-117 in major depressive disorder (MDD). Top line results from these studies were announced on May 26, 2016. Additional information from recent MIN-202 studies carried out in insomnia and MDD will also be presented. Top line results from both of these studies were announced earlier this year. MIN-202 is under joint development with Janssen Pharmaceutica NV.
The presentation will be web cast and accessible through the investor relations section of the Company’s web site,http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, which has successfully completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has successfully completed Phase IIa and Phase Ib clinical trials in insomnia and MDD, respectively; MIN-117, which has successfully completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visitwww.minervaneurosciences.com.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Crown Bioscience Inc.19.6.2018 14:01 | pressemeddelelse
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents
Glatfelter19.6.2018 13:45 | pressemeddelelse
Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million
Lithium Werks19.6.2018 09:02 | pressemeddelelse
Lithium Werks and Endrich agree pan-Asian battery distribution deal
PubMatic, Inc.19.6.2018 09:02 | pressemeddelelse
PubMatic Launches PubMatic Cloud to Evolve the SSP Business Model
Vricon18.6.2018 22:24 | pressemeddelelse
Vricon's disruptive 3D GEOINT technology fuels company growth
Cisco18.6.2018 14:02 | pressemeddelelse
Goldman Sachs and Cisco to Host Tech Talk on Data Center Networking
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum